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Abstract
Introduction Heat shock protein 70 (Hsp70) is a well-known
anti-apoptotic protein that blocks multiple steps in the stress-
induced apoptotic pathway. Enhanced Hsp70 expression has
previously been demonstrated in rheumatoid arthritis (RA)
fibroblast-like synoviocytes (FLSs). The authors investigated the
role of Hsp70 in the survival of RA FLSs in a sodium
nitroprusside (SNP)-treated environment.
Methods Targeted knock-down of Hsp70 was performed by
RNA interference in RA FLSs at passage 3-7. After SNP
treatment, the morphological features of apoptosis were
observed by phase-contrast microscopy. Cell survival was
measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assays and by flow cytometric
analysis after propidium iodide (PI) staining. Bcl-2 expression
and signaling pathways (Akt, extracellular signal-regulated
kinase, p38, c-Jun N-terminal kinase) were examined with or
without Hsp70 downregulation.
Results Hsp70 downregulation in RA FLSs, induced by small
interfering RNA (siRNA), was confirmed by reverse
transcriptase-polymerase chain reaction and Western blotting.
When treated with SNP, Hsp70 downregulated cells showed
markedly less cell blebbing, cytoplasmic condensation, and
nuclear shrinkage than non-downregulated control cells.
Furthermore, Hsp70 downregulated cells were found to survive
better than control cells in MTT assays (mean of absorbance
ratio, 4.39 in target cells versus 1.00 in control siRNA-treated
cells versus 1.09 in lipofectamine-treated cells, P = 0.001) and
according to PI staining results (mean M1 ratio, 0.21 in target
cells versus 1.00 in control siRNA-treated cells versus 1.03 in
lipofectamine-treated cells, P = 0.001). Bcl-2 expression and
Akt phosphorylation were higher in Hsp70 downregulated RA
FLSs than in control cells. When cells were treated with
LY294002, a potent phosphoinositide 3-kinase inhibitor, Akt
phosphorylation and Bcl-2 levels were reduced and Hsp70
downregulation no longer had a cytoprotective effect.
Conclusions Knock-down of Hsp70 protects RA FLSs from
nitric oxide-induced apoptosis by activating the Akt signaling
pathway. These results suggest that Hsp70 has a pro-apoptotic
role in RA FLSs.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disorder
that involves mainly joint synovium. One of the major charac-
teristics of RA synovium is the tumor-like growth of fibroblast-
like synoviocytes (FLSs) that invade adjacent articular carti-
lage and bone [1]. Although the mechanism of FLS hyperpla-
sia in RA is not fully understood, it is explained in part by
excessive survival and/or anti-apoptotic signals to FLSs trans-
mitted by inflammatory cells and cytokines. For example, it has
been well established that tumor necrosis factor-alpha (TNF-
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α), a key cytokine in RA, activates genes that mediate prolifer-
ative and inflammatory responses [2]. Other anti-apoptotic
apparatuses expressed in RA FLSs include FLIP (Fas-associ-
ated death domain-like interleukin [IL]-1β-converting enzyme-
inhibitory protein) [3], sentrin [4], mutated p53 [5,6], and the
activation of the nuclear factor-kappa-B or the Akt signaling
pathways or both [7,8].
Heat shock protein 70 (Hsp70) is a molecular chaperone that
is rapidly induced by physical and chemical stresses. The anti-
apoptotic function of Hsp70 depends on its ability to interact
with protein substrates that are not always associated with the
chaperoning activity. The mechanisms by which Hsp70 exerts
its anti-apoptotic function encompass the inhibition of the c-
Jun N-terminal kinase (JNK) signaling pathway, caspase acti-
vation, mitochondrial cytochrome c release, and apoptosome
formation [9]. Although the anti-apoptotic role of Hsp70 has
been demonstrated in a number of studies in various cell types
and under different conditions, several other studies have
shown that the overexpression of Hsp70 promotes cell death,
which suggests that Hsp70 has dual functionality depending
on cell and stimulus type [10-12]. It has been reported that the
expression of Hsp70 is higher in both tissue and cultured RA
FLSs than in the FLSs of osteoarthritis and that inflammatory
cytokines, such as TNF-α and IL-1β, that exist abundantly in
RA joint fluid further increase Hsp70 expression in cultured RA
FLSs [13]. However, no study has investigated the actual role
of Hsp70 in the survival of RA FLSs. In this study, we investi-
gate the effect of Hsp70 downregulation on RA FLS apoptosis
induced by sodium nitroprusside (SNP), a nitric oxide (NO)
donor.
Materials and methods
Primary culture of fibroblast-like synoviocyte derived 
from rheumatoid arthritis patient synovium
Synovium was obtained from the affected joints of five patients
undergoing joint replacement surgery (Table 1). Individual age
data were removed to protect the identities of patients. All
patients met the 1987 American Rheumatism Association cri-
teria for RA [14]. The isolation and culture of FLSs were per-
formed as previously described [5]. Briefly, minced synovium
was incubated with 1 mg/mL collagenase type VIII (Sigma-
Aldrich, St. Louis, MO, USA) in serum-free RPMI 1640
medium (Gibco, now part of Invitrogen Corporation, Carlsbad,
CA, USA) for 1 hour at 37°C, filtered, extensively washed, and
cultured in Dulbecco's modified Eagle's medium (DMEM) (Inv-
itrogen Corporation) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen Corporation). Cells were allowed to
adhere overnight, and adherent FLSs were grown in DMEM
containing 10% FBS. FLSs at passages 3 to 7 were used for
the experiments. This study was approved by the Institutional
Review Board of Seoul National University Hospital (#H-
0603-134-170), and informed consent was obtained from
participants.
Cell treatments
Cells were incubated with TNF-α (R&D Systems, Minneapolis,
MN, USA) at 10 ng/mL for 8 hours where indicated. To induce
apoptosis, cells were treated with 1 mM SNP (Sigma-Aldrich)
for 24 hours in a light-shielded state. LY294002 (Cell Signal-
ing Technology, Inc., Danvers, MA, USA) at 2 to 10 μM was
added to culture media to block phosphoinositide 3-kinase
(PI3K) activity.
Reverse transcriptase-polymerase chain reaction
Total mRNA was extracted from cultured RA FLSs, and single-
stranded cDNA was synthesized from mRNA using reverse
transcription kits (Intron Biotechnology, Seoul, Korea). The
polymerase chain reaction (PCR) amplification of hsp70 was
performed with an initial Taq (Invitrogen Corporation) activa-
tion at 95°C for 5 minutes followed by 25 amplification cycles
of 15 seconds at 95°C, 30 seconds at 60°C, and 30 seconds
at 60°C. The primers used were forward 5'-GGA-GGC-GGA-
GAA-GTA-CAA-3' and reverse 5'-GCT-GAT-GAT-GGG-
GTT-ACA-3' [15]. The semi-quantitative measurements were
performed using gapdh  (glyceraldehyde-3-phosphate dehy-
drogenase) as an internal reference.
Table 1
Clinical data of five patients with rheumatoid arthritis at the time of joint surgerya
Patient Disease durationb, months Site of surgery Medication
1 74 Knee MTX 15 mg/wk, SSZ 1 g/d, Pd 5 mg/d
2 60 Knee NSAIDs
3 97.5 Knee Pd 10 mg/d
4 121 Knee Pd 10 mg/d
5 180 Hip HCQ 200 mg/d
aAge of the patients was 57.0 ± 15.6 years (age range 35 to 73 years), and they were all female. bDisease duration is the time interval between 
symptom onset of rheumatoid arthritis and joint replacement surgery. HCQ, hydroxychlorquine; MTX, methotrexate; NSAID, nonsteroidal anti-
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Western blotting
Total cell lysates were separated on 10% denaturating poly-
acrylamide gels and transferred to polyvinylidene difluoride
membranes. The primary antibodies used were mouse mono-
clonal anti-Hsp70 antibody (donated by the Department of
Biochemistry, Seoul National University College of Medicine,
Korea), rat monoclonal anti-constitutional Hsp70 (Hsc70) anti-
body (StressGen Biotechnologies Corporation, Victoria, BC,
Canada), rabbit monoclonal anti-Bcl-2 antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), rabbit monoclonal
anti-Akt/phospho-Akt, anti-extracellular signal-regulated
kinase (ERK)/phospho-ERK, anti-c-Jun N-terminal kinase
(JNK)/phospho-JNK, and anti-p38/phospho-p38 antibodies
(Cell Signaling Technology, Inc.), and rabbit monoclonal anti-
actin antibody (Sigma-Aldrich). The secondary antibodies
used were horseradish peroxidase-conjugated anti-mouse
IgG (The Jackson Laboratory, Bar Harbor, ME, USA), anti-rab-
bit IgG (The Jackson Laboratory), or anti-rat IgG (StressGen
Biotechnologies Corporation) antibodies. Signals were devel-
oped using an ECL (enhanced chemiluminescence) system
(Amersham Biosciences, now part of GE Healthcare, Little
Chalfont, Buckinghamshire, UK).
Transfection using small interfering RNA
FLSs were seeded at a density of 1.0 to approximately1.5 ×
106/mL and incubated overnight in antibiotics-free DMEM
supplemented with 10% FBS. The following day, cells were
washed with phosphate-buffered-saline, and then OPTI-MEM
reduced serum medium (Invitrogen Corporation) was added
to cells. Hsp70-specific small interfering RNA (siRNA) (for-
ward 5'-CGA-CGG-AGA-CAA-GCC-CAA-GTT-3' and
reverse 5'-CUU-GGG-CUU-GUC-UCC-GUC-GTT-3';
Invitrogen Corporation) [15] and a nucleic acid transferring
agent, lipofectamine 2000 (Invitrogen Corporation), were
incubated together in OPTI-MEM reduced serum medium for
15 minutes at room temperature to form an siRNA-lipo-
fectamine complex. The siRNA-lipofectamine complex-con-
taining medium was added to cells to a final siRNA
concentration of 25 nM. Six hours later, the complex-contain-
ing medium was exchanged with antibiotics-free DMEM sup-
plemented with 10% FBS. The second round of transfection
was performed 48 hours after the first transfection, using the
same method. Cells transfected twice with 25 nM control
siRNA of medium GC content (Invitrogen Corporation) and
cells transfected with lipofectamine only were used as
controls.
Figure 1
Expression and specific knock-down of heat shock protein 70 (Hsp70) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) Expression and specific knock-down of heat shock protein 70 (Hsp70) in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs).  Hsp70 was 
expressed in cultured RA FLSs as shown by reverse transcriptase-polymerase chain reaction (a) and Western blotting (b). Hsp70 levels were 
increased by tumor necrosis factor-alpha (TNF-α) treatment. Gene knock-down was specific for Hsp70; constitutional Hsp70 (Hsc70) levels were 
unaffected (c). The experiments were performed in RA FLSs from five patients and these are representative figures. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; siRNA, small interfering RNA.Arthritis Research & Therapy    Vol 11 No 4    Kang et al.
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Assessment of cell viability and apoptosis
Morphological changes were observed after SNP treatment
under a phase-contrast microscope (Olympus, Tokyo, Japan).
In addition, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) (Sigma-Aldrich) assays were performed to
assess cell viability. Apoptotic cell fractions (sub-G0/G1 por-
tions or M1 fractions) were measured by propidium iodide (PI)
(Sigma-Aldrich) staining and flow cytometry (FACSCalibur;
BD Biosciences, San Jose, CA, USA). The absorbance (meas-
ured at 570 nm) and apoptotic fraction were normalized to
those of control siRNA-treated cells in each experiment.
Statistical analysis
Continuous values were presented as mean ± standard devi-
ation. Analysis of variance (ANOVA) was used to compare
mean values of more than two groups. Two-tailed P values of
less than 0.05 were considered significant. All statistical cal-
culations were performed using SPSS version 12 (SPSS Inc.,
Chicago, IL, USA).
Results
Expression of Hsp70 in cultured rheumatoid arthritis 
fibroblast-like synoviocytes with or without tumor 
necrosis factor-alpha
Hsp70 expressions in cultured RA FLSs were confirmed by
reverse transcriptase-PCR and Western blotting (Figure 1a,
b). They were increased after 8 hours of treatment with 10 ng/
mL TNF-α.
Specific knock-down of Hsp70 expression in rheumatoid 
arthritis fibroblast-like synoviocyte
Targeted knock-down of Hsp70 by specific siRNA was
observed in RA FLSs (Figure 1c). Because knock-down was
incomplete after a single transfection, a second round of trans-
Figure 2
Effect of heat shock protein 70 (Hsp70) knock-down on nitric oxide-induced apoptosis in rheumatoid arthritis (RA) fibroblast-like synoviocytes  (FLSs) Effect of heat shock protein 70 (Hsp70) knock-down on nitric oxide-induced apoptosis in rheumatoid arthritis (RA) fibroblast-like synoviocytes 
(FLSs).  To induce apoptosis, cells were treated with 1 mM sodium nitroprusside (Sigma-Aldrich, St. Louis, MO, USA) for 24 hours in a light-
shielded state. The cytoprotective effect of Hsp70 knock-down was observed by phase-contrast microscopy (a). MTT assays showed that cell viabil-
ity was significantly greater in Hsp70 downregulated FLSs (left) than in control FLSs (middle = control small interfering RNA [siRNA]-treated cells, 
right = lipofectamine-treated cells) (mean of relative absorbance, 4.39 ± 2.82 versus 1.00 ± 0.00 versus 1.09 ± 0.30, P = 0.001 by analysis of var-
iance [ANOVA]) (b). Propidium iodide (PI) analysis showed that the apoptotic fraction in Hsp70 downregulated FLSs (left) was significantly lower 
than in control FLSs (middle = control siRNA-treated cells, right = lipofectamine-treated cells) (mean of relative M1, 0.21 ± 0.16 versus 1.00 ± 0.00 
versus 1.03 ± 0.36, P = 0.001 by ANOVA) (c). All experiments were performed in triplicate using five RA FLS samples. The histograms and error 
bars indicate mean and standard deviation of relative absorbance, respectively. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.Available online http://arthritis-research.com/content/11/4/R130
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fection was performed 48 hours after the first transfection.
Almost complete knock-down of Hsp70 expression was then
achieved and sustained for up to 72 hours. The expression of
Hsc70 was unaffected (observed at 48 hours after the second
transfection) by Hsp70-specific siRNA despite its 86% amino
acid homology with Hsp70 (Figure 1c).
Effect of Hsp70 knock-down on nitric oxide-induced 
apoptosis in rheumatoid arthritis fibroblast-like 
synoviocyte
After treatment with SNP (1 mM) for 24 hours, cell blebbing
and cytoplasmic condensation were markedly lower in Hsp70
downregulated RA FLSs than in control RA FLSs (Figure 2a).
MTT assays showed that the cell viability of Hsp70 downreg-
ulated FLSs was significantly higher than that of control FLSs
(mean of relative absorbance of 4.39 ± 1.82 in target cells ver-
sus 1.00 ± 0.00 in control siRNA-treated cells versus 1.09 ±
0.30 in lipofectamine-treated cells, P = 0.001) (Figure 2b). PI
analysis also revealed significantly lower apoptotic fractions in
Hsp70 downregulated FLSs than in control FLSs (mean of rel-
ative M1 of 0.21 ± 0.16 in target cells versus 1.00 ± 0.00 in
control siRNA-treated cells versus 1.03 ± 0.36 in lipo-
fectamine-treated cells, P = 0.001) (Figure 2c).
Intracellular Bcl-2 levels and signaling pathways
Because Bcl-2 is known to block NO-induced apoptosis
[16,17], we investigated whether Hsp70 downregulation
causes any change in cellular Bcl-2 level. Bcl-2 expression
was higher in Hsp70 downregulated cells than in controls with
or without SNP treatment (Figure 3a). We then explored the
signaling pathways involved in the cytoprotective effect of
Hsp70 downregulation. Western blotting revealed that Akt
phosphorylation was higher in Hsp70 downregulated RA FLS
than in controls. However, the ERK, p38, and JNK pathways
were unaffected by Hsp70 downregulation (Figure 3b).
Effect of Akt phosphorylation on the survival of 
rheumatoid arthritis fibroblast-like synoviocyte
LY294002 (10 μM) decreased Akt phosphorylation to the
control level, and this inhibition of Akt phosphorylation was
LY294002 dose-dependent, which indicated that Akt is phos-
phorylated via PI3K (Figure 4a). In addition, Bcl-2 levels were
found to be closely correlated with phospho-Akt levels (Figure
4a). Furthermore, Hsp70 downregulated cells did not exhibit
resistance to SNP treatment when Akt signaling was inhibited,
and this loss of Hsp70 downregulation-induced cytoprotec-
tion was dose-dependent of LY294002 (Figure 4b).
Discussion
This study shows that Hsp70 is expressed in RA FLSs and
that knock-down of Hsp70 protects RA FLSs from NO-
induced apoptosis via the Akt signaling pathway. This result is
consistent with that of Schett and colleagues [13], who found
that RA FLSs express Hsp70 and that this expression is
increased by inflammatory cytokines, such as TNF-α. On the
other hand, Schick and colleagues [18] found that Hsc70, and
Figure 3
Bcl-2 level and signaling pathways in heat shock protein 70 (Hsp70) downregulated rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) Bcl-2 level and signaling pathways in heat shock protein 70 (Hsp70) downregulated rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs).  
Levels of Bcl-2, a well-known inhibitor of nitric oxide-induced apoptosis, were increased by Hsp70 knock-down with or without sodium nitroprusside 
(SNP) treatment (a). Western blotting showed that phospho-Akt levels were higher in Hsp70 downregulated RA FLSs than in controls (b). The 
experiments were performed in five RA FLS samples and the representative figures are shown. ERK, extracellular signal-regulated kinase; JNK, c-Jun 
N-terminal kinase.Arthritis Research & Therapy    Vol 11 No 4    Kang et al.
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not Hsp70, was overexpressed in RA synovial tissues and cul-
tured FLSs. They suspected that anti-Hsp70 antibody in the
study of Schett and colleagues might have cross-reacted with
Hsc70. However, the specificity of the anti-Hsp70 antibody
used in the present study has been characterized previously
[19]. Furthermore, our observation that anti-Hsp70 antibody
demonstrated Hsp70 downregulation by siRNA, whereas anti-
Hsc70 antibody showed consistent Hsc70 expression, further
supports specific antibody reactivity with Hsp70 in the present
study.
Unexpectedly, we observed that Hsp70 downregulation pro-
tected RA FLSs from NO-induced apoptosis. This finding sug-
gests that Hsp70 may be a pro-apoptotic protein in RA FLSs.
Our results indicate that hsp70 interferes with Akt phosphor-
ylation by binding an upstream protein of the Akt signaling
pathway in RA FLSs. However, in vivo, abundant intracellular
anti-apoptotic apparatuses generated by external survival/
growth signals appear to overcome the negative effect of
Hsp70 on Akt phosphorylation and on cell survival.
The anti-apoptotic effect mediated by Akt signaling pathway
activation after Hsp70 knock-down in RA FLSs is consistent
with the findings of the previous report, namely, that Akt phos-
phorylation is an important mechanism to protect RA FLSs
from NO-induced apoptosis [20]. Akt phosphorylation has
been shown to regulate Hsp70 expression [21,22]. However,
to the best of our knowledge, this is the first report to suggest
that Hsp70 is involved in the regulation of the Akt signaling
pathway. However, the direct molecular mechanism by which
Hsp70 knock-down promotes Akt phosphorylation remains to
be determined.
Recently, anti-cytokine therapies for RA have entered the spot-
light [23-25]. However, response to anti-cytokine agents is
often only partial and some patients are refractory to these
agents. Therefore, treatments with different mechanisms need
to be combined. Although blocking anti-apoptotic proteins is a
candidate strategy, the results of the present study do not sup-
port the notion that the downregulation of Hsp70 promotes
the regression of hyperplastic synovium. Alternatively, the in
vivo  effect of Hsp70 knock-down might differ from that
observed in vitro. Recently, the biological role of extracellular
Figure 4
Effect of Akt phosphorylation on rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) survival Effect of Akt phosphorylation on rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) survival.  LY294002, a potent PI3K (phosphoinositide 3-
kinase) inhibitor, decreased Akt phosphorylation in a dose-dependent manner, and Bcl-2 levels were found to be closely correlated with phospho-
Akt levels (a). When cells were treated with LY294002, the cytoprotective effect of heat shock protein 70 (Hsp70) knock-down disappeared (b). 
The experiments were performed using three RA FLS samples (a, b) in triplicate (b). The representative figures are shown. MTT, 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide; siRNA, small interfering RNA.Available online http://arthritis-research.com/content/11/4/R130
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hsp70, particularly in terms of immune response, including the
cross-presentation of antigenic peptide and maturation of anti-
gen-presenting cells (APCs), was substantively updated [26-
28]. Because the synovial fluid of patients with RA contains
high levels of soluble Hsp70, which interacts with APCs via a
plethora of surface receptors [29], the effect of Hsp70 knock-
down is likely to be complex in vivo.
Conclusions
In summary, this study shows that Hsp70 is expressed in RA
FLSs and that knock-down of Hsp70 protects RA FLSs from
NO-induced apoptosis by activating the Akt signaling path-
way. These results suggest that Hsp70 has a pro-apoptotic
role in RA FLS.
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